Navigation Links
Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
Date:5/9/2013

THOUSAND OAKS, Calif. and ZHEJIANG, China, May 9, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Zhejiang Beta Pharma Co., Ltd.  (Zhejiang Beta Pharma) today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix® (panitumumab) in the Chinese market. Together, Amgen and Zhejiang Beta Pharma aim to quickly and efficiently deliver Vectibix to patients in China.

The joint venture will benefit from Zhejiang Beta Pharma's strong expertise in the development and commercialization of molecularly targeted therapies as well as Zhejiang Beta Pharma's industry-leading oncology sales network in China. Zhejiang Beta Pharma's China capabilities are complementary to Amgen's global expertise in the development and manufacturing of human therapeutics.

"This joint venture brings us one step closer to providing Chinese patients with Amgen's medicines and supports our strategy of expanding in key, fast-growing markets," said Anthony C. Hooper , executive vice president at Amgen. "We are pleased to have the opportunity to join forces with Zhejiang Beta Pharma, a leader in developing and commercializing innovative medicines that shares our goal of making a new treatment option available to colorectal cancer patients in China."

"Amgen is a pioneer and a global leader in the biotech industry. Our partnership with Amgen will be of long-term strategic significance not only for Zhejiang Province, but also for the whole medical community in China," said Lieming Ding, chairman of Zhejiang Beta Pharma.  "We share Amgen's passion for developing molecularly targeted therap
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Research and Markets  ( http://www.researchandmarkets.com/research/4lw2mn/global_a_dialyzer ) ... A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor ) ... The Global A Dialyzer Reprocessing Machine ... a professional and in-depth study on the current ... The report provides a basic overview of ...
(Date:6/1/2015)... 1, 2015  Boston Biomedical, an industry leader in ... stem cell (CSC) pathways, will present clinical data today ... tumor types at the 2015 American Society of Clinical ... . Data presented at ASCO highlight the ... targets STAT3, leading to inhibition of the critical genes ...
(Date:6/1/2015)... YORK , June 1, 2015   ... of Open, Transparent and Connected financial marketplaces for ... Incorporated, a San Diego -based ... traded on OTCQB®, America,s only public venture market ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ...
Breaking Medicine Technology:Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 2Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 4Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 5Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 6Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 7OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2
... InVitria,( http://www.InVitria.com ), a leading global ... safety and time to market for companies,in ... and,diagnostics industry, will be an exhibitor and ... in Anaheim, California on September,23-26. ( http://www.ibclifesciences.com/B8171/overview.xml ...
... Bionovo, Inc.,(Nasdaq: BNVI ) today announced ... for,the American Society for Pharmacology and Experimental Therapeutics, ... of,Liquiritigenin, a Bioactive Compound Isolated from the Chinese ... one of the active compounds of MF101, Bionovo,s ...
Cached Medicine Technology:InVitria Showcases Cell Culture Productivity Enhancers at BioProcess International 2Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate 2Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate 3
(Date:6/1/2015)... 01, 2015 EBSCO Health , ... introduced DynaMed Plus™ , a cross-platform evidence-based clinical ... It provides clinicians with the ideal blend of evidence ... paths. , DynaMed Plus is a significant enhancement ... the most frequently updated evidence-based content. DynaMed Plus content ...
(Date:6/1/2015)... June 01, 2015 KC and Monica ... $88,000 of the best superfood products in ... floods in Texas. , "Monica and I are ... News in distributing Living Fuel Super Meals - SuperBerry®, ... millennial floods in Texas," KC Craichy said. "We have ...
(Date:6/1/2015)... Atlanta, GA (PRWEB) June 01, 2015 ... leading publisher of clinical journals in the areas of ... pleased to announce that it has expanded upon its ... newest journal, Hospital Medicine Practice, in a mobile ... smartphones and tablets. , “We are very excited ...
(Date:6/1/2015)... The session, entitled “Building the Blueprint ... president of Elektrobit Automotive Americas, senior representatives from ... will be moderated by Andy Gryc of CX3 Marketing. ... complexity of in-vehicle software in connected vehicles and autonomous ... how the wider ecosystem can fit into new vehicle ...
(Date:6/1/2015)... 2015 Strategic Radiology (SR) announced today ... joined forces with the SR coalition of progressive, independent ... alignment, RRG will now have access to collective resources ... clinical quality, and deployment of subspecialized radiology services. With ... member and affiliate US based radiology group practices. ...
Breaking Medicine News(10 mins):Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 2Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 3Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 4Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 2Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 3Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 2Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 3Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 2Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 3Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 4
... (NYSE: WST ) today announced that Donald E. ... Federici, Chief,Financial Officer, will be presenting at the 2008 ... 11, 2008 in New York City., A copy ... the,investor link of the Company,s website at http://www.westpharma.com ...
... BIOSAFE Laboratories, Inc.,the developer of the BIOSAFE ... have announced the availability of a limited,number of ... identify diabetic and,pre-diabetic children and adolescents. The BIOSAFE ... an immediate fasting glucose reading and,a mail-in laboratory ...
... IPC The,Hospitalist Company, Inc. (Nasdaq: IPCM ... that it closed its previously announced initial,public offering ... that the,underwriters of the offering have exercised their ... stock from the selling,stockholders at the public offering ...
... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged ... of healthy aging, today announced,the debut of Pyratine-6(TM) ... of Dermatology in San Antonio, Texas., Pyratine-6(TM), ... to be effective in correcting visible signs of ...
... EnterpriseIQ Supports Device Manufacturer,s Continued Growth and Compliance, ... a leader in the,design and development of Enterprise ... II Medical Manufacturing for its comprehensive ERP,software, EnterpriseIQ. ... medical,device manufacturing industry, so does the level of ...
... Center had sleeplessness, other problems, study shows , , TUESDAY, ... the World Trade Center terrorist attacks boosted behavioral problems ... researchers at the Mount Sinai School of Medicine in ... years of age who lived in or attended preschool ...
Cached Medicine News:Health News:West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference 2Health News:BIOSAFE Labs and Glycemion to Provide Free Diabetes Risk Assessment Kits to U.S. School Children 2Health News:IPC The Hospitalist Company, Inc. Announces Closing of IPO and Exercise of Underwriters' Over-Allotment Option 2Health News:Senetek PLC Announces Debut of Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology 2Health News:Phase II Medical Manufacturing Selects IQMS for ERP Solution 2Health News:Phase II Medical Manufacturing Selects IQMS for ERP Solution 3Health News:9/11 Exposure Linked to Behavior Trouble in Kids 2
Anti-MPO ANCA EIA Auto-Immune Markers 013-MPO-96 Myeloperoxidase...
... the quantitative determination of Immunoglobulin E ... atopic allergic diseases such as atopic ... been shown to exhibit increased total,immunoglobulin ... is also known as the,reagenic antibody. ...
... Complexes from patient serum or plasma, standards and ... microtiter wells. After a washing step, an ... to the Fc region of human IgG. ... pipetted followed by a stopping step. The ...
... captured with the CR-DGi can be viewed immediately, ... the beginning. Because the images are digital, ... such as telemedicine and electronic filing. The ... quality and ease of use. It's the latest ...
Medicine Products: